Schaeffer DF, Méndez-Sánchez N

Language: English
References: 6
Page: 374-375
PDF size: 27.41 Kb.

Text Extraction

Original abstract

The American Association for the Study of Liver Diseases guidelines recommend the use of all available markers for improving the accuracy of the diagnosis of small hepatocellular carcinoma (HCC). To determine whether clathrin heavy chain (CHC), a novel HCC marker, is effective in combination with glypican 3 (GPC3), heat shock protein 70, and glutamine synthetase, we compared the performances of a three-marker panel (without CHC) and a fourmarker panel (with CHC) in a series of small HCCs (≤ 2 cm) and nonsmall HCCs by core biopsy with a 20- to 21-gauge needle.

REFERENCES

1. Bruix J, Sherman M. Practice Guidelines Committee, AASLD. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

2. Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multidetector row helical CT in patients with cirrhosis. Radiology 2005; 234: 460-7.

3. Forner A, Vilana R, Ayuso C, Bianchi L, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104.

4. Di Tommaso L, Franchi G, Park YN et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in heaptocellular nodules in cirrhosis. Hepatology 2007; 45: 725-34.

5. Di Tommaso L, Destro A, Seok JY, et al. The application of the markers (HSP70, PPC3 and GS) in liver biopsies is useful for the detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-54.

6. Seimiya M, Tomonaga T, Matsushita K, Sunaga M, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formi-minotransferase cyclodeaminase. Hepatology 2008; 48: 519-30.